NYSE:PTHS
Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc.'s revenue was $16.8M in fiscal 2025. Free cash flow was −$22.7M, −135.1% of revenue, and the diluted share count rose 237.3%.Summary generated from Pelthos Therapeutics Inc.'s SEC filings. Latest annual report filed Mar 19, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$16.8M
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross margin76.3%
Operating margin−193.1%
Net margin−257.9%
ROICn/a
Return on equity−239.5%
Debt / equityn/a
Free cash flow−$22.7M
FCF margin−135.1%
Share count change+237.3%
Financials
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | n/a | n/a | 0 | 17 |
| Operating income | −2 | −7 | −8 | −32 |
| Net income | −2 | −7 | −8 | −43 |
| Free cash flow | n/a | n/a | −6 | −23 |
Recent filings
- 4Insider transaction report
Oct 6, 2026 - 4Insider transaction report
Oct 6, 2026 - 8-KDirector or officer change
Oct 1, 2026 - DEF 14AProxy statement
Aug 18, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 10-Q/AAmended quarterly report for the period ended Mar 31, 2026
Aug 13, 2026 - 8-KNon-reliance on previously issued financial statements
Aug 13, 2026